Risk Factors for Leukopenia with Valganciclovir Prophylaxis in CMV High Risk Cardiothoracic Transplant Recipients

被引：0
|
作者：
Brueckner, A. J. [1 ]
Doligalski, C. T. [1 ]
Logan, A. T. [1 ]
机构：
[1] Tampa Gen Hosp, Pharm, Tampa, FL 33606 USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2017年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1122
引用
收藏
页码：S365 / S366
页数：2
相关论文
共 50 条
  • [31] Leukopenia in renal transplant recipients, risk factors and complications.
    Khan, Ali R.
    Patel, Anita
    AlHakeem, Moushen
    Goggins, Mariella
    Parasuraman, Ravi
    Karthikeyan, Vanji
    Venkat, K. K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 364 - 364
  • [32] Valganciclovir approved for the prevention of CMV in high-risk kidney, kidney-pancreas transplant recipients
    不详
    DIALYSIS & TRANSPLANTATION, 2003, 32 (11) : 646 - 646
  • [33] Combination prophylaxis in CMV high risk heart transplant recipients: A single center experience
    Van Aelst, Lucas N. L.
    Droogne, Walter
    Voros, Gabor
    Van Cleemput, Johan
    CLINICAL TRANSPLANTATION, 2023, 37 (03)
  • [34] CMV Reactivation Using Valganciclovir vs Valacyclovir in Moderate Risk Heart Transplant Recipients
    Varnado, S.
    Brink, H.
    Balk, J.
    Raichlin, E.
    Lowes, B.
    Vongooru, H.
    Burdorf, A.
    Um, J.
    Moulton, M.
    Siddique, A.
    Zolty, R.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S284 - S284
  • [35] Eight Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients
    El Hajj, S.
    Kim, M.
    Azzi, J.
    Gabardi, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 504 - 504
  • [36] Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis
    Katada, Yoshiki
    Nakagawa, Shunsaku
    Nagao, Miki
    Umemura, Keisuke
    Itohara, Kotaro
    Nishikawa, Asami
    Hashi, Sachiyo
    Katsube, Yurie
    Hira, Daiki
    Ohsumi, Akihiro
    Nakajima, Daisuke
    Date, Hiroshi
    Terada, Tomohiro
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25 (06)
  • [37] Factors Associated with the Development of CMV Viremia in High-Risk (D+/R-) Renal Transplant Patients on Valganciclovir Prophylaxis
    Limaye, A.
    Hauser, I.
    Loveless, M.
    Mu, Y.
    Blumberg, E.
    Jardine, A.
    Humar, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 69 - 69
  • [38] Impact of a Dosing Change for CMV Prophylaxis on Rates of Leukopenia in Liver Transplant Recipients
    Emmett, G.
    Yeager, S.
    Belden, K.
    Glorioso, J.
    Schulte, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S796 - S796
  • [39] Impact of Prolonging CMV Prophylaxis in High Risk (CMV D plus /R-) Lung Transplant Recipients
    Khan, B.
    Husain, S.
    Binnie, M.
    Chow, C.
    Martinu, T.
    Chaparro, C.
    Keshavjee, S.
    Singer, L. G.
    Tikkanen, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S319 - S319
  • [40] The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
    Humar, A.
    Lebranchu, Y.
    Vincenti, F.
    Blumberg, E. A.
    Punch, J. D.
    Limaye, A. P.
    Abramowicz, D.
    Jardine, A. G.
    Voulgari, A. T.
    Ives, J.
    Hauser, I. A.
    Peeters, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) : 1228 - 1237
12345